BioCrossroads has named Eli Lilly CEO, Dave Ricks, the recipient of the 2024 August M. Watanabe Life Sciences Champion of the ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

“We still have a situation where there are far more patients who would like to have the treatment than what both Eli Lilly ...

Ricks is being recognized for his contributions to Indiana’s life sciences sector and his global impact on health care ...

Business leaders including Jamie Dimon, Howard Schultz, and Elon Musk weigh in on Election Day for Donald Trump, Kamala ...

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Viking Therapeutics has announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.

Bank of America upgrades Peloton to Buy, citing potential for revenue growth and operational improvements under new CEO.

In interviews with Reuters, eight U.S. obesity specialists at universities and large health systems described a different ...

In the effort to expand approaches to treating Alzheimer’s beyond targeting amyloid, some companies have sought to target ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...